BioSpace News Archive

Bristol Myers Squibb announced that its Board of Directors has elected two new independent directors, Ms. Paula A. Price and Mr. Derica W. Rice, who will join the Board, effective September 1, 2020.

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on novel and targeted oncology therapies, announced the pricing of an underwritten public offering of 21,666,667 shares of its common stock at a public offering price of $3.00 per share.

Leading institutional investors commit $320 million through a common stock private investment in public equity (“PIPE”) led by Bain Capital, Perceptive Advisors, Pfizer Inc. and other top-tier healthcare investors

Results of the First 12 patients enrolled in the Phase II NMIBC Clinical Study Demonstrate a 58.3% Response 90 Days Post Initial Treatment

Phase 2 Study for Diabetic Peripheral Neuropathic Pain Underway, Additional Studies Planned in Other Areas of Neuropathic Pain

Second-quarter revenue of $2.7 billion decreased 4% on a reported basis, 1% on a constant currency basis and 2% on an operational basis1

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer, today announced that it will report second quarter 2020 financial results after the close of U.S. financial markets on Thursday, August 6, 2020. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corpo